Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
Associated Disease
uterine corpus endometrial carcinoma
Source Database
CIViC Evidence
Description
Eight uterine cancer cell lines (four with ERBB2 amplification and four without) were treated with scalar concentrations of afatinib. Primary chemotherapy-resistant USC cell lines harbouring ERBB2 gene amplification were sensitive to afatinib exposure and significantly more sensitive than non-amplified cell lines.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/886
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/306
Rating
2
Evidence Type
Predictive
Disease
Uterine Corpus Endometrial Carcinoma
Evidence Direction
Supports
Drug
Afatinib
Evidence Level
D
Clinical Significance
Sensitivity/Response
Pubmed
25268372
Drugs
Drug NameSensitivitySupported
AfatinibSensitivitytrue